Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.
Bain BJ.
Haematologica. 2010 May;95(5):696-8. doi: 10.3324/haematol.2009.021675.
Myeloid/lymphoid neoplasm with FGFR1 rearrangement.
Germans SK, Chen M.
Blood. 2021 Sep 9;138(10):912. doi: 10.1182/blood.2021012168.
Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Freyer CW, Hughes ME, Carulli A, Bagg A, Hexner E.
Expert Rev Anticancer Ther. 2023 Apr;23(4):351-359. doi: 10.1080/14737140.2023.2192930. Epub 2023 Mar 29.
Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1.
Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN.
Am J Clin Pathol. 2015 Sep;144(3):377-92. doi: 10.1309/AJCPMORR5Z2IKCEM.
Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement.
Yan Y, Qu S, Liu J, Li C, Yan X, Xu Z, Qin T, Jia Y, Pan L, Gao Q, Jiao M, Li B, Gale RP, Xiao Z.
Leuk Lymphoma. 2023 Sep;64(9):1605-1610. doi: 10.1080/10428194.2023.2226277. Epub 2023 Jun 24.
Myeloid neoplasm with ETV6::ACSl6 fusion: landscape of molecular and clinical features.
Su Z, Liu X, Hu W, Yang J, Yin X, Hou F, Wang Y, Zhang J.
Hematology. 2022 Dec;27(1):1010-1018. doi: 10.1080/16078454.2022.2117206.
Hypogonadotropic hypogonadism.
Layman LC.
Endocrinol Metab Clin North Am. 2007 Jun;36(2):283-96. doi: 10.1016/j.ecl.2007.03.010.
Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H, Wang W, Song J, Tang G, Zhang X, Tang Z, Srivastava J, Shah B, Medeiros LJ, Zhang L.
Leuk Res. 2020 Dec;99:106460. doi: 10.1016/j.leukres.2020.106460. Epub 2020 Oct 6.
Myeloid neoplasms with eosinophilia.
Reiter A, Gotlib J.
Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27.
Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.
Savage N, George TI, Gotlib J.
Int J Lab Hematol. 2013 Oct;35(5):491-500. doi: 10.1111/ijlh.12057. Epub 2013 Mar 13.
